Table 3

 Clinicopathological features that are significantly different (p<0.05) between the various groups of sporadic breast cancers, cancers in patients with BRCA1 or BRCA2 germline mutations and in patients with breast cancer who are at different risks of hereditary disease on the basis of family history (Claus’s criteria)

Clinicopathological features differing in groups of patients with breast cancer
Intermediate risk of hereditary diseaseHigh risk of hereditary diseaseGermline mutations in BRCA1Germline mutations in BRCA2
ER, oestrogen receptor; MAI, mitotic activity index; PR, progesterone receptor; T size, tumour size.
Continuous variables were compared with the Mann–Whitney test and discrete variables with the χ2 test.
Sporadic breast cancerAge, T size, p53, PR, p21, cyclin E, cyclin D1Age, MAI, T size, Ki67, p53, ER, cyclin A, EGFR, gradeAge, MAI, Ki67, p53, ER, PR, cyclin A, EGFR, gradeAge, cyclin E, EGFR, grade
Breast cancer in patients at intermediate risk of hereditary diseaseMAI, T size, Ki67, ER, PR, cyclin A, EGFR, gradeAge, MAI, Ki67, ER, PR, p21, cyclin A, EGFR, gradeKi67, cyclin E, EGFR, grade
Breast cancer in patients at high risk of hereditary diseaseT size, p27T size, p53, ER, cyclin A
Breast cancer in patients with germline mutations in BRCA1Age, Ki67, PR, cyclin A